Sign In
Buy KHTRF
$5.99
+0.0800 (+1.35%)
At Close: Jun 03, 2026
Notice of Knight Therapeutics' First Quarter 2024 Results Conference Call
07:30am, Thursday, 02'nd May 2024
MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2024 fin
Knight Therapeutics Inc. (KHTRF) Q4 2023 Earnings Call Transcript
12:15pm, Thursday, 21'st Mar 2024
Knight Therapeutics Inc. (KHTRF) Q4 2023 Earnings Call Transcript
Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results
07:30am, Thursday, 21'st Mar 2024
MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financ
Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call
07:30am, Thursday, 14'th Mar 2024
MONTREAL, March 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and y
Knight Therapeutics Inc. Celebrates its First Decade of Success
07:30am, Wednesday, 28'th Feb 2024
MONTREAL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it is marking its 10-year ann
Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil
05:30pm, Wednesday, 21'st Feb 2024
MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, Unit
Knight Therapeutics Announces Launch of Bijuva® in Canada
07:30am, Tuesday, 06'th Feb 2024
MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a Pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of BIJUVA® (estradiol
Knight Therapeutics Announces Product Launch for IMVEXXY® in Canada
07:30am, Thursday, 04'th Jan 2024
MONTREAL, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of IMVEXXY® in Canada
Knight Therapeutics Inc. (KHTRF) Q3 2023 Earnings Call Transcript
01:42am, Sunday, 12'th Nov 2023
Knight Therapeutics Inc. (OTCPK:KHTRF) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Samira Sakhia - President and Chief Executive Officer Arvind Utchanah - Chief F
Knight Therapeutics Reports Third Quarter 2023 Results
07:30am, Thursday, 09'th Nov 2023
MONTREAL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financi
Notice of Knight Therapeutics' Third Quarter 2023 Results Conference Call
07:30am, Thursday, 02'nd Nov 2023
MONTREAL, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 fi
Knight Therapeutics Inc. places No. 90 on The Globe and Mail's fifth-annual ranking of Canada's Top Growing Companies
04:30pm, Monday, 02'nd Oct 2023
MONTREAL, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it placed No. 90 on the 2023 Report on Business ranking of Can
Knight Therapeutics Reports Second Quarter 2023 Results
07:30am, Thursday, 10'th Aug 2023
MONTREAL, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financi
Notice of Knight Therapeutics' Second Quarter 2023 Results Conference Call
08:32pm, Thursday, 03'rd Aug 2023
MONTREAL, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2023 f
Knight Therapeutics Inc. (KHTRF) Q1 2023 Earnings Call Transcript
04:50pm, Saturday, 13'th May 2023
Knight Therapeutics Inc. (OTCPK:KHTRF) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Samira Sakhia – President and Chief Executive Officer Arvind Utchanah – Chief F
